SCHEMBL19100263

SCHEMBL19100263

CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3F)ncnc2cc1OCCOC(F)F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.70
ERBB2 P04626 13/20 0.70
KDR P35968 1/20 0.59
CIT O14578 1/20 0.55
GAK O14976 1/20 0.55
EPHB6 O15197 1/20 0.55
RIPK2 O43353 1/20 0.55
STK10 O94804 1/20 0.55
ABL1 P00519 1/20 0.55
LCK P06239 1/20 0.55
LYN P07948 1/20 0.55
RET P07949 1/20 0.55
CHRM2 P08172 1/20 0.55
MET P08581 1/20 0.55
HCK P08631 1/20 0.55
SRC P12931 1/20 0.55
PHKG2 P15735 1/20 0.55
ADRA2B P18089 1/20 0.55
ERBB3 P21860 1/20 0.55
AXL P30530 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Maleic Acid SCHEMBL20637507 0.97 EGFR (0.67) EGFRERBB2KDRCITGAK
SCHEMBL19100280 0.94 EGFR (0.68) EGFRERBB2KDR
SCHEMBL19125881 0.90 EGFR (0.58) EGFRERBB2KDR
SCHEMBL19100193 0.90 EGFR (0.68) EGFRERBB2KDR
SCHEMBL19100056 0.88 EGFR (0.89) EGFRERBB2CITGAKEPHB6
SCHEMBL19124461 0.88 EGFR (0.63) EGFRERBB2KDR
Maleic Acid SCHEMBL20637511 0.87 EGFR (0.65) EGFRERBB2KDRGAKABL1
SCHEMBL19100423 0.86 EGFR (0.67) EGFRERBB2KDRGAKRIPK2
SCHEMBL19100269 0.85 EGFR (0.64) EGFRERBB2GAKRIPK2LCK
SCHEMBL19100065 0.85 EGFR (0.64) EGFRERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190016689-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2019-01-17 US claimed
EP-3400216-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS Trillium Therapeutics Inc. (CA) 2018-11-14 EP claimed
WO-2017117680-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2017-07-13 WO claimed
US-20190016689-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2019-01-17 US disclosed
US-20190016689-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2019-01-17 US disclosed
WO-2017117680-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2017-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016689-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 EGFR 1/4885ERBB2 2/4885KDR 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.